文献速递流行病学与生物统计临床试验与 GCP

腹主动脉瘤初级保健筛查:美国预防服务工作组更新证据报告与系统综述

Primary Care Screening for Abdominal Aortic Aneurysm: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2019-01-01

对65岁以上男性一次性筛查邀请可降低AAA相关死亡率(OR 0.65)和破裂率(OR 0.62),但全因死亡率无显著获益(RR 0.99)。小动脉瘤早期手术与监测相比,AAA相关死亡和全因死亡无显著差异。

要点

  • 65岁以上男性一次性AAA筛查可降低AAA相关死亡率和破裂率。
  • 筛查未显示全因死亡率获益,且增加手术操作率。
  • 小动脉瘤(3.0-5.4 cm)早期手术与监测相比无生存获益。

核心结论

  • 对65岁以上男性一次性AAA筛查与AAA相关死亡率和破裂率降低相关,但无全因死亡率获益。
  • 筛查导致更高的择期手术率,但长期生活质量无差异。
  • 小动脉瘤早期手术治疗与监测相比,AAA相关死亡或全因死亡无显著差异。

研究设计与样本

  • 纳入AAA筛查利益与危害的试验,以及小动脉瘤(3.0-5.4 cm)治疗利益与危害的试验和队列研究。
  • 检索MEDLINE、PubMed(仅出版商提供)、DARE和Cochrane CENTRAL截至2018年9月的英文文献,监测至2019年7月。
  • 两位研究者独立审查摘要和全文并提取数据。
  • 使用Peto法合并AAA相关死亡率、破裂和手术的比值比(OR),使用DerSimonian and Laird随机效应模型合并全因死亡率的计算风险比。

关键数值与推荐

  • 小动脉瘤(3.0-5.4 cm)早期手术试验(4项,n=3314)显示,与监测相比,AAA相关死亡或全因死亡无显著差异。
  • 早期手术组手术量显著增加。

临床怎么用

  • 可考虑对65岁以上男性提供一次性AAA筛查邀请,以降低AAA相关死亡和破裂风险。
  • 筛查不改善全因死亡率,且增加手术操作,需权衡利弊。
  • 小动脉瘤(3.0-5.4 cm)优先监测而非早期手术,尤其女性手术风险更高。

局限性

  • 全因死亡率结果基于计算风险比,可能受混杂影响。
  • 小动脉瘤治疗证据主要来自早期试验,现代管理策略可能不同。
  • 女性筛查证据有限,结果主要适用于男性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ruptured abdominal aortic aneurysms (AAAs) have mortality estimated at 81%. OBJECTIVE: To systematically review the evidence on benefits and harms of AAA screening and small aneurysm treatment to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed (publisher supplied only), Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials for relevant English-language studies published through September 2018. Surveillance continued through July 2019. STUDY SELECTION: Trials of AAA screening benefits and harms; trials and cohort studies of small (3.0-5.4 cm) AAA treatment benefits and harms. DATA EXTRACTION AND SYNTHESIS: Two investigators independently reviewed abstracts and full-text articles and extracted data. The Peto method was used to pool odds ratios (ORs) for AAA-related mortality, rupture, and operations; the DerSimonian and Laird random-effects model was used to pool calculated risk ratios for all-cause mortality. MAIN OUTCOMES AND MEASURES: AAA and all-cause mortality; AAA rupture; treatment complications. RESULTS: Fifty studies (N = 323 279) met inclusion criteria. Meta-analysis of population-based randomized clinical trials (RCTs) estimated that a screening invitation to men 65 years or older was associated with a reduction in AAA-related mortality over 12 to 15 years (OR, 0.65 [95% CI, 0.57-0.74]; 4 RCTs [n = 124 926]), AAA-related ruptures over 12 to 15 years (OR, 0.62 [95% CI, 0.55-0.70]; 4 RCTs [n = 124 929]), and emergency surgical procedures over 4 to 15 years (OR, 0.57 [95% CI, 0.48-0.68]; 5 RCTS [n = 175 085]). In contrast, no significant association with all-cause mortality benefit was seen at 12- to 15-year follow-up (relative risk, 0.99 [95% CI 0.98-1.00]; 4 RCTs [n = 124 929]). One-time screening was associated with significantly more procedures over 4 to 15 years in the invited group compared with the control group (OR, 1.44 [95% CI, 1.34-1.55]; 5 RCTs [n = 175 085]). Four trials (n = 3314) of small aneurysm surgical treatment demonstrated no significant difference in AAA-related mortality or all-cause mortality compared with surveillance over 1.7 to 12 years. These 4 early surgery trials showed a substantial increase in procedures in the early surgery group. For small aneurysm treatment, registry data (3 studies [n = 14 424]) showed that women had higher surgical complications and postoperative mortality compared with men. CONCLUSIONS AND RELEVANCE: One-time AAA screening in men 65 years or older was associated with decreased AAA-related mortality and rupture rates but was not associated with all-cause mortality benefit. Higher rates of elective surgery but no long-term differences in quality of life resulted from screening.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Guirguis-Blake JM, Beil TL, Senger CA, et al. Primary Care Screening for Abdominal Aortic Aneurysm: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31821436. doi:10.1001/jama.2019.17021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。